Product Details: ACTH 1-34 (Peptide)
ACTH 1-34 is a shortened peptide segment produced from the full-length adrenocorticotropic hormone (ACTH 1-39), known for its retained bioactivity and functional domains in experimental animals. This particular fragment, which consists of the first 34 amino acids of the parent peptide, has been broadly explored in controlled research contexts because to its ability to retain important signaling capabilities associated with the ACTH molecule.
ACTH 1-34 has been shown in non-human biological systems to be effective in activating melanocortin receptors, particularly those implicated in adrenal signaling cascades. These interactions stimulate glucocorticoid production, metabolic modulation, and cellular energy regulation across a wide range of test models.
Mechanism of Action
Under experimental conditions, such an interaction may activate signaling pathways involved in corticosteroid production. These pathways are associated with cellular responses that regulate metabolism and communicate in response to stress.
The peptide is also utilized to study processes involved in the hypothalamic-pituitary-adrenal (HPA) axis. The observed effects vary depending on the experimental model and conditions used.
Chemical Properties of ACTH 1-34 (Peptide)
- Molecular Formula: C₂₀₇H₃₀₈N₅₆O₅₈S
- Molecular Weight: 4541 g/mol
- CAS Number: 12279-41-3
- IUPAC Name: H-DL-Ser-DL-Tyr-DL-Ser-DL-Met-DL-Glu-DL-His-DL-Phe-DL-Arg-DL-Trp-Gly-DL-Lys-DL-Pro-DL-Val-Gly-DL-Lys-DL-Lys-DL-Arg-DL-Arg-DL-Pro-DL-Val-DL-Lys-DL-Val-DL-Tyr-DL-Pro-DL-Asn-Gly-DL-Ala-DL-Glu-DL-Asp-DL-Glu-DL-Ser-DL-Ala-DL-Glu-DL-Ala-DL-Phe-DL-Pro-DL-Leu-DL-Glu-DL-Phe-OH
- Synonyms: ACTH 1-34, Adrenocorticotropic Hormone 1-34
Research Applications of ACTH 1-34
-
Adrenal Signaling Studies
ACTH 1-34 is used in controlled studies that examine adrenal receptor activity. It may help researchers observe how peptide fragments influence signaling pathways.
-
Corticosteroid Pathway Research
Some studies focus on how this peptide connects to corticosteroid-related signaling in laboratory models. Cellular responses are measured under controlled conditions.
-
HPA Axis Investigation
This compound is commonly applied in research involving the hypothalamic-pituitary-adrenal axis to study regulatory signaling processes.
Why Buy ACTH 1-34 from BehemothLabz
BehemothLabz supplies research compounds with a focus on consistency, quality, and transparency. Each batch of ACTH 1-34 is produced with Third-party Certificates of Analysis available to verify identity and purity. This helps ensure that each product meets expected research specifications.
For researchers studying endocrine signaling and peptide-based pathways, ACTH 1-34 from BehemothLabz offers a consistent and dependable research material.
For products availability, message @behemothLabz.com (307) 429-0990
Disclaimer: This information is for educational purposes only. We do not allow the human consumption of our products. All products are sold strictly for laboratory and research experiments.
Please review the Terms and Conditions before purchasing. Please research the scientific uses of this product before making any purchases.
Packaging and labeling may differ from what is shown on the website.
References
- Schwyzer, R. (1977). ACTH: A short introductory review. Annals of the New York Academy of Sciences, 297, 3–26. https://pubmed.ncbi.nlm.nih.gov/202097/
- Gallo-Payet, N., & Payet, M. D. (2003). Mechanism of action of ACTH: Beyond cAMP. Microscopy Research and Technique, 61(3), 275–287. https://pubmed.ncbi.nlm.nih.gov/12768535/
- Mountjoy, K. G., et al. (1992). The cloning of a family of genes that encode the melanocortin receptors. Science, 257(5074), 1248–1251. https://pubmed.ncbi.nlm.nih.gov/1325670/
- Smith, A. I., & Funder, J. W. (1988). Proopiomelanocortin processing in the pituitary, central nervous system, and peripheral tissues. Endocrine Reviews, 9(1), 159–179. https://pubmed.ncbi.nlm.nih.gov/2835774/
- PubChem. (n.d.). Adrenocorticotropic hormone (1-34). National Center for Biotechnology Information.
